| pubmed-article:21401865 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21401865 | lifeskim:mentions | umls-concept:C0023884 | lld:lifeskim |
| pubmed-article:21401865 | lifeskim:mentions | umls-concept:C0450127 | lld:lifeskim |
| pubmed-article:21401865 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:21401865 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:21401865 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21401865 | pubmed:dateCreated | 2011-3-30 | lld:pubmed |
| pubmed-article:21401865 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:abstractText | The selectin antagonist known as recombinant P-selectin glycoprotein ligand IgG (rPSGL-Ig) blocks leukocyte adhesion and protects against transplantation ischemia reperfusion injury (IRI) in animal models. This randomized (1:1) single-center double-blind 47-patient phase 2 study with 6-month follow-up assessed rPSGL-Ig's safety and impact on early graft function at 1 mg/kg systemic dose with pretransplant allograft ex vivo treatment in deceased-donor liver transplant recipients. Safety was assessed in all patients, whereas efficacy was assessed in a prospectively defined per-protocol patient set (PP) by peak serum transaminase (TA) and bilirubin values, and normalization thereof. In PP patients, the incidence of poor early graft function (defined as peak TA >2500 U/L or bilirubin >10 mg/dL), average peak liver enzymes and bilirubin, normalization thereof and duration of primary and total hospitalization trended consistently lower in the rPSGL-Ig group compared to placebo. In patients with donor risk index above study-average, normalization of aspartate aminotransferase was significantly improved in the rPSGL-Ig group (p < 0.03). rPSGL-Ig treatment blunted postreperfusion induction versus placebo of IRI biomarker IP-10 (p < 0.1) and augmented cytoprotective IL-10 (p < 0.05). This is the first clinical trial of an adhesion molecule antagonist to demonstrate a beneficial effect on liver transplantation IRI and supported by therapeutic modulation of two hepatic IRI biomarkers. | lld:pubmed |
| pubmed-article:21401865 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21401865 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21401865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21401865 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21401865 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21401865 | pubmed:issn | 1600-6143 | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:KatzEE | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:BusuttilR WRW | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:GjertsonD WDW | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:HemmerichSS | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:Kupiec-Weglin... | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:RabeUU | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:WatkinsTT | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:SquiersE CEC | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:CheadleCC | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:EhrlichEE | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:LipshutzG SGS | lld:pubmed |
| pubmed-article:21401865 | pubmed:author | pubmed-author:PonthieuxSS | lld:pubmed |
| pubmed-article:21401865 | pubmed:copyrightInfo | ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons. | lld:pubmed |
| pubmed-article:21401865 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21401865 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:21401865 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21401865 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21401865 | pubmed:pagination | 786-97 | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:meshHeading | pubmed-meshheading:21401865... | lld:pubmed |
| pubmed-article:21401865 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21401865 | pubmed:articleTitle | rPSGL-Ig for improvement of early liver allograft function: a double-blind, placebo-controlled, single-center phase II study. | lld:pubmed |
| pubmed-article:21401865 | pubmed:affiliation | Dumont UCLA Transplant Center, Los Angeles, CA, USA. magnin@ccf.org | lld:pubmed |
| pubmed-article:21401865 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21401865 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21401865 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21401865 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:21401865 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
